



05/25/01

Anticipated Classification
of this Application:
Class 536 Subclass _____

Prior Application:

Examiner MurphyGroup Art Unit 1646Attorney's Boxer

Docket

No. 1795/57155-AA

JPW/BJA

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

May 25, 2001

jc872 U.S. PTO
09/866248
05/25/01

S I R:

This is a request for filing a X CONTINUATION

____ DIVISIONAL _____ CONTINUATION-IN-PART application under

X 37 C.F.R. §1.53(b) _____ 37 C.F.R. §1.53(d), of pending prior applicationSerial No. 09/255,368 filed on February 22, 1999 of

Christophe P.G. Gerald, Kenneth A. Jones, James A. Bonini, And Beth Borowsky for
Inventor(s)

DNA ENCODING MAMMALIAN NEUROPEPTIDES FF (NPFF) RECEPTORS AND USES THEREOF

Title of Invention

X

Enclosed is a copy of the prior application, as originally
filed and an affidavit or declaration verifying it as a
true copy.

2.

A verified statement to establish small entity status under
37 C.F.R. §1.9 and 1.27

____ is enclosed.

____ was filed in the prior application and such status
is still proper and desired (37 C.F.R. §1.28(a)).

3. X The filing fee is calculated as follows:CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	28 - 20	=	8	X	9	18	= \$	\$144
Independent Claims	12-3	=	9	X	40	80	= \$	\$720
Multiple Dependent Claims Presented:		<u>X</u> Yes _____ No			135	270	= \$	\$270
					BASIC FEE		\$355	\$710
					TOTAL FEE		\$	\$1844

*If the difference in Col. 1 is
less than zero, enter "0" in
Col. 2.

Filing an application pursuant to this section expressly abandons the
parent application.

Cont.Div.
Page 2

4. X The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Account No. 03-3125.
- X Any additional filing fees required under 37 C.F.R. §1.16.
- X Any patent application processing fees under 37 C.F.R. §1.17.
- The issue fees set forth in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
5. X Three copies of this sheet are enclosed.
6. X A check in the amount of \$ 1844 is enclosed.
7. Cancel claims .
8. Amend the specification by inserting before the first line the sentence: --This is a continuation division of application Serial No. , filed .--
9. X 21 Sheet(s) of informal X formal drawing(s) is/are enclosed.
10. Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
11. Priority of application No. filed on in (country) is claimed under 37 U.S.C. §119.
- The certified copy of the priority application has been filed in prior application Serial No. , filed .
12. X The prior application is assigned of record to Synaptic Pharmaceutical Corporation.
13. X A preliminary amendment is enclosed.
14. X The power of attorney in the prior application is to:

John P. White (Reg. No. 28.678); Christopher C. Dunham (Reg. No. 22.031); Norman H. Zivin (Reg. No. 25.385); Jay H. Maioli (Reg. No. 27.213); William E. Pelton (Reg. No. 25.702); Robert D. Katz (Reg. No. 30.141); Peter J. Phillips (Reg. No. 29.691); Wendy E. Miller (Reg. No. 35.615); Richard S. Milner (Reg. No. 33.970); Albert Wai-Kit Chan (Reg. No. 36.479); Robert T. Maldonado (Reg. 38.232); Paul Teng (40.837); George M. MacDonald (Reg. No. 39.284); Richard F. Jaworski (Reg. No. 33.515); Elizabeth M. Wieckowski (Reg. No. 42.226); and Pedro C. Fernandez (Reg. No. 41.741)

Applicants: Christophe P.G. Gerald et al
U.S. Serial No.: Not Yet Known
Filed: Herewith

Cont/Div./FWC
Page 3

- (a) X The power appears in the original papers in the prior application.
- (b) Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c) X Address all future communications to:
(May only be completed by applicant,
or attorney or agent of record.)

John P. White

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

15. X

Also enclosed Express Mail Certificate of Mailing No.

EL628787487US dated May 25, 2001

An extra set of figures, a Sequence Listing and a CRF Sequence Listing.
I hereby verify that the attached papers are a true copy
of prior application Serial No. as originally
filed on .

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

May 25, 2001
Date

John P. White
Signature John P. White, Reg. No. 28,678

 INVENTOR(S)
 ASSIGNEE OF COMPLETE INTEREST
 X ATTORNEY OR AGENT OF RECORD
 FILED UNDER 37 C.F.R. §1.34(a)

Address of Signator:

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald et al
U.S. Serial No. : Not Yet Known
Filed : Herewith
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE
FF(`NPFF) RECEPTORS AND USES THEREOF

1185 Ave of the Americas
New York, New York 10036
May 25, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231
Attn: Box Patent Application

Sir:

**EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION**

"Express Mail" Mailing Label Number: EL628787487US

Date of deposit: May 25, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. Box Patent Application.

Printed Name

Derek Barbce
Derek Barbce

Respectfully submitted,

John P. White
John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Case 1:01-pat-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald, et al.
Serial No. : Not Yet Known
Filed : Herewith
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF
(NPFF) RECEPTORS AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
February 22, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231


SIR:

**STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)
FOR ABOVE-IDENTIFIED APPLICATION**

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the contents of the Sequence Listing enclosed herewith as **Exhibit A** and the contents of the computer readable form of the sequence listings are identical.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,


Jennifer H. Burdman
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400